论文部分内容阅读
高血压作为一种全球性心血管危险因素,近年仍在不断增长。2002年,中国高血压的患病率达18.8%;目前的患病率更高,患者总数可能超过2亿,合并多种危险因素的患者比例增加[1-2]。在非药物治疗基础上,降压药物如钙拮抗剂、血管紧张素转换酶抑制剂(angiotensin converting enzyme inhibitor,ACEI)、血管紧张素受体拮抗剂(angiotensin receptor blockers,ARB)、利尿剂、β受体阻滞剂等,仍是降压治疗的
Hypertension, as a global cardiovascular risk factor, is still growing in recent years. In 2002, the prevalence rate of hypertension in China reached 18.8%; the current prevalence rate is even higher, with the total number of patients exceeding 200 million. The proportion of patients with multiple risk factors increased [1-2]. On the basis of non-drug treatment, antihypertensive drugs such as calcium antagonists, angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blockers (ARB), diuretics, β Receptor blockers, etc., is still antihypertensive treatment